AMBUJACEM - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.6
| Stock Code | AMBUJACEM | Market Cap | 1,03,828 Cr. | Current Price | 420 ₹ | High / Low | 625 ₹ |
| Stock P/E | 29.0 | Book Value | 206 ₹ | Dividend Yield | 0.48 % | ROCE | 8.80 % |
| ROE | 8.77 % | Face Value | 2.00 ₹ | DMA 50 | 498 ₹ | DMA 200 | 538 ₹ |
| Chg in FII Hold | -0.11 % | Chg in DII Hold | 0.23 % | PAT Qtr | 227 Cr. | PAT Prev Qtr | 1,571 Cr. |
| RSI | 26.4 | MACD | -25.1 | Volume | 28,31,852 | Avg Vol 1Wk | 40,86,182 |
| Low price | 418 ₹ | High price | 625 ₹ | PEG Ratio | 1.40 | Debt to equity | 0.02 |
| 52w Index | 0.82 % | Qtr Profit Var | -87.1 % | EPS | 13.7 ₹ | Industry PE | 27.0 |
📊 Analysis: AMBUJACEM shows moderate fundamentals for long-term investment. ROE at 8.77% and ROCE at 8.80% are relatively weak, indicating limited capital efficiency. Debt-to-equity at 0.02 reflects a nearly debt-free balance sheet, which is positive. The P/E ratio of 29.0 is slightly above the industry average of 27.0, suggesting mild overvaluation. Dividend yield at 0.48% is modest. The PEG ratio of 1.40 indicates fair valuation relative to growth. Technical indicators (RSI 26.4, MACD negative, price below DMA 50 & 200) show strong bearish momentum. Overall, the company is financially stable but currently facing earnings weakness, making it a cautious candidate for long-term investment.
💰 Ideal Entry Zone: ₹410 – ₹430, closer to support levels, aligning with valuation comfort and technical positioning.
📈 Exit / Holding Strategy: Existing holders should maintain a medium-term horizon (2–3 years) but monitor earnings closely. Profit booking can be considered if the price revisits ₹600–₹620. Long-term holding is not recommended unless ROE/ROCE improve significantly and profit growth stabilizes.
Positive
- Debt-to-equity at 0.02 indicates a nearly debt-free balance sheet.
- Stable valuation compared to industry average P/E (29.0 vs 27.0).
- EPS at ₹13.7 supports earnings visibility.
- DII holdings increased (+0.23%), signaling domestic institutional confidence.
Limitation
- Weak ROE (8.77%) and ROCE (8.80%) highlight poor capital efficiency.
- Dividend yield (0.48%) is modest compared to peers.
- Technical indicators (MACD negative, RSI near 26) show strong bearish momentum.
Company Negative News
- Quarterly PAT declined sharply (₹227 Cr vs ₹1,571 Cr), showing earnings weakness.
- Quarterly profit variance (-87.1%) highlights volatility.
- Sharp correction from ₹625 to ₹420 shows investor caution.
- FII holdings decreased (-0.11%), reflecting reduced foreign investor confidence.
Company Positive News
- PEG ratio of 1.40 suggests fair valuation relative to growth.
- Strong liquidity with average weekly volume above 40 lakh shares.
Industry
- Industry P/E at 27.0 is slightly lower than company’s P/E (29.0), suggesting peers may offer marginally better value.
- Cement sector growth supported by infrastructure expansion and housing demand.
Conclusion
⚖️ AMBUJACEM is financially stable with low debt and fair valuation, but weak ROE/ROCE and sharp profit decline make it a cautious candidate for long-term investment. Ideal entry is around ₹410–₹430. Existing holders should maintain a 2–3 year horizon, booking profits near ₹600–₹620. While fundamentals are stable, earnings volatility and weak technicals warrant cautious positioning.